Ribavirin: Is It a Mutagen for Hepatitis C Virus?

Gastroenterology

Volumn 132, Issue 5, 2007, Pages 2050-2052

  Perelson, Alan S ^a   Layden, Thomas J ^b  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LEVOVIRIN; MUTAGENIC AGENT; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADD ON THERAPY; ANALYTIC METHOD; CELL CULTURE; DRUG MEGADOSE; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; MUTAGENESIS; MUTATION RATE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REPLICON; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 34247607729     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.077     Document Type: Editorial

References (21)

1. Hofmann W.P., Polta A., Herrmann E., Mihm U., Kronenberger B., Sonntag T., Lohmann V., Schonberger B., Zeuzem S., and Sarrazin C. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132 (2007) 921-930
2. Lutchman G., Danehower S., Song B.-C., Liang J.T., Hoofnagle J.H., Thomson M., and Ghany M.G. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132 (2007) 1757-1766
3. Dixit N.M., and Perelson A.S. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 63 (2006) 832-842
4. Feld J.J., and Hofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
5. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., Sallie R., Park Y., Yurdaydin C., Swain M., Kleiner D.E., Mahaney K., and Hoofnagle J.H. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 897-903
6. Pawlotsky J.M., Dahari H., Neumann A.U., Hezode C., Germanidis G., Lonjon I., Castera L., and Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126 (2004) 703-714
7. Asahina Y., Izumi N., Enomoto N., Uchihara M., Kurosaki M., Onuki Y., Nishimura Y., Ueda K., Tsuchiya K., Nakanishi H., Kitamura T., and Miaake S. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43 (2005) 623-629
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
9. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
10. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J., and International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
11. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
12. Herrmann E., Lee J.H., Marinos G., Modi M., and Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37 (2003) 1351-1358
13. Enomoto M., Nishiguchi S., Kohmoto M., Tamori A., Habu D., Takeda T., Seki S., and Shiomi S. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 11 (2004) 448-454
14. Dixit N.M., Layden-Almer J.E., Layden T.J., and Perelson A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432 (2004) 922-924
15. Layden-Almer J.E., Ribeiro R.M., Wiley T., Perelson A.S., and Layden T.J. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37 (2003) 1343-1350
16. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of HCV RNA during antiviral therapy. Hepatology. In press.
17. Bronowicki J.P., Ouzan D., Asselah T., Desmorat H., Zarski J.P., Foucher J., Bourliere M., Renou C., Tran A., Melin P., Hezode C., Chevalier M., Bouvier-Alias M., Chevaliez S., Montestruc F., Lonjon-Domanec I., and Pawlotsky J.M. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131 (2006) 1040-1048
18. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98 (2001) 6895-6900
19. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6 (2000) 1375-1379
20. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76 (2002) 8505-8517
21. Lanford R.E., Guerra B., Lee H., Averett D.R., Pfeiffer B., Chavez D., Notvall L., and Bigger C. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77 (2003) 1092-1104